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Abstract
Background: We have previously shown that use of an EC brush device in combination with the
Rovers Cervex-Brush (SurePath broom) offered no significant improvement in EC recovery. Here
we determine if use of additional collection devices enhance the diagnostic utility of the SurePath
Pap for gynecologic cytology.
Methods:  After informed consent, 37 women ages 18–56 receiving their routine cervical
examinations were randomized into four experimental groups. Each group was first sampled with
the SurePath broom then immediately re-sampled with an additional collection device or devices.
Group 1: Rover endocervix brush (n = 8). Group 2: Medscand CytoBrush Plus GT (n = 7). Group
3: Rover spatula + endocervix brush (n = 11). Group 4: Medscand spatula + CytoBrush Plus GT (n
= 11).
Results:  Examination of SurePath broom-collected cytology yielded the following abnormal
diagnoses: atypia (n = 2), LSIL (n = 5) and HSIL (n = 3). Comparison of these diagnoses to those
obtained from paired samples using the additional collection devices showed that use of a second
and or third device yielded no additional abnormal diagnoses. Importantly, use of additional devices
did not improve upon the abnormal cell recovery of the SurePath broom and in 4/10 cases under-
predicted or did not detect the SurePath broom-collected lesion as confirmed by cervical biopsy.
Finally, in 36/37 cases, the SurePath broom successfully recovered ECs. Use of additional devices,
in Group 3, augmented EC recovery to 37/37.
Conclusions: Use of additional collection devices in conjunction with the SurePath broom did not
enhance diagnostic utility of the SurePath Pap. A potential but not significant improvement in EC
recovery might be seen with the use of three devices.
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Background
In gynecologic cytology, sampling of both the ecto and
endocervix is critical to increasing Pap test sensitivity [1].
Controversy still exists, however, as to whether "all-in-
one" broom-type devices appropriately sample the cervix.
While agreement has been reached on the importance of
sampling the transformation zone [2], concern as to how
proximal the transformation zone is to the face of the cer-
vix [3] has lead to lingering doubt over how effective cur-
rent broom-type sampling devices are compared to a
separate spatula and endocervical brush [4]. This debate
has been re-energized by the generalized adoption of the
liquid-based Pap test in the United States. Currently, two
FDA approved liquid-based Pap tests are available, one
manufactured by Cytyc (Boxborough, MA) and one man-
ufactured by TriPath Care Technologies (Burlington, NC).
Currently, the ThinPrep Pap Test (Cytyc) and the SurePath
Pap (TriPath Care Technologies) offer two types of sam-
pling devices a broom-type device or a spatula + cytobrush
combination. It has been reported, that the use of the
broom-type device for both the ThinPrep Pap Test and the
SurePath Pap appears to under-sample the endocervix
resulting in increased limited-bys due to lack of an EC
component [4,5]. We have not observed this phenome-
non and have previously shown that the SurePath Pap
reduced by 33% the number of limited-by cases due to
lack of an EC component when compared to the tradi-
tional Pap test when the SurePath Pap utilized the Sure-
Path broom and the traditional Pap test utilized the
spatula + EC brush combination [6]. In that failure to
sample the endocervix can coincide with failure to sample
the transformation zone we sought, in this study, to deter-
mine if additional sampling devices used in conjunction
with the SurePath broom improved SurePath Pap EC
recovery and/or increased SurePath Pap diagnostic
effectiveness.
Methods
Cervical/endocervical sampling
After study design approval from the Carle Clinic Associa-
tion Institutional Review Board and informed consent, 37
women ages 18–56 receiving their routine cervical exami-
nations were sampled with the SurePath broom. This
device, which is packaged with the SurePath Pap, is the
Rovers Cervex-Brush (Rovers Medical Devices, Oss, The
Netherlands). Its use followed the manufactures recom-
mendations of 5 full clockwise rotations. The same
patient was immediately re-sampled with either the Rov-
ers endocervix brush, patient group 1; the Medscand Cyto-
brush Plus GT (Medscand Medical, Malmö, Sweden),
patient group 2: the Rovers endocervix brush + Rovers
Spatula, patient group 3; or the Medscand Cytobrush Plus
GT + Medscand Pap Perfect Spatula, patient group 4. All
devices had "pop-off" heads. The SurePath broom device
was collected into CytoRich Preservative vials (TriPath
Care Technologies, Burlington, NC) and processed rou-
tinely using the PrepStain Slide Processor (TriPath Care
Technologies, Burlington, NC). In samples using multiple
collection devices, all devices, including the SurePath
broom, were placed in a single collection vial and proc-
essed as above.
Slide diagnosis
The diagnostic terminology used was derived from the
1991 revision of the Bethesda System (TBS) [7-9]. The
diagnostic categories available were: 1) no intraepithelial
lesion (NIL), 2) inflammation/repair (BCC), 3) atypical
squamous cells of uncertain significance (ASC-US), 4)
low-grade squamous intraepithelial lesion (LSIL), 5)
high-grade squamous intraepithelial lesion (HSIL) 6)
squamous cancer, 7) atypical glandular cells of uncertain
significance (AGUS) and 8) glandular cancer. ECs were
considered present if they appeared as a group of 6 or
more cells. Slides were reviewed following standard prac-
tice. Slide screening was performed blinded to the sample
collection device type. Screening of alternate device collec-
tions from the same patient were screened by the same
cytotechnologist. Screened slides were re-reviewed by a
senior cytotechnologist and a pathologist for diagnoses
other than NIL. Re-reviewers were blinded to device type
and all slides from a particular patient were reviewed by
the same senior cytotechnologist and pathologist. Quality
control rescreen of slides did not result in revision of a
diagnosis.
Cytology/cervical biopsy comparison
All cases where the cytology diagnosis was ASC-US or
more serious underwent colposcopic-guided cervical
biopsy (cervical biopsy). Cases were excluded from analy-
sis if the: 1) cytology and corresponding tissue diagnosis
were separated in time by more than 6 months; 2) cytol-
ogy and/or corresponding cervical biopsy were not per-
formed and interpreted within the Carle Clinic
Association/Hospital system. In cases where multiple cer-
vical biopsies were performed, the cytology closest in tem-
poral relationship to the cervical biopsy was correlated.
No cervical biopsies met the exclusion criteria.
Statistical analysis
All analyses were performed using SAS statistical software
(Cary, NC). Data comparisons were made using the Stu-
dent's paired t-test, the Sign Test and the Wilcoxon Signed
Rank test for analysis of non-parametric data.
Results
Diagnostic utility of the SurePath broom with 
supplemental EC sampling
We have previously shown that use of the Surgipath C-E
brush (Richmond, IL) in combination with the SurePath
broom did not increase EC recovery in womenBMC Women's Health 2004, 4:6 http://www.biomedcentral.com/1472-6874/4/6
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undergoing a SurePath Pap [6]. This previous study, how-
ever, did not investigate whether use of an EC brush
enhanced SurePath Pap diagnostic utility. Therefore, to
determine if an EC brush aided recovery of cytologically
abnormal cells, EC brushes from Rovers and Medscand
were examined. Tables 1 and 2 show results of women
who were first sampled with the SurePath broom then
immediately re-sampled with either a Rovers (Table 1) or
Medscand EC brush device (Table 2). In group 1 patients
(Table 1), 1/8 had LSIL identified by cytology after use of
the SurePath broom. In addition, EC cells were identified
in all 8 cases. Immediate re-sampling of group 1 patients
with the Rover brush did not result in increased abnormal
diagnoses. In fact, 3/8 cases had less than 5000 squamous
cells/slide and required a diagnosis of QNS. In these QNS
cases, no EC cells were seen. Importantly, follow-up cervi-
cal biopsy confirmed the SurePath broom-identified LSIL.
This case was associated with a Rovers brush QNS.
When group 2 patients were examined by cytology after
using the SurePath broom (Table 2), 1/7 patients had
ASC-US and 2/7 had HSIL. As above, adequate EC cells
were identified in all SurePath broom cases. Immediate
re-sampling of group 2 patients with the Medscand brush
did not provide additional diagnostic utility. Importantly,
follow-up cervical biopsy confirmed the SurePath broom-
identified HSILs. In one of these HSIL cases, the Medscand
brush was associated with a QNS. Taken together these
findings indicate that addition of a Rover endocervix
brush or Medscand CytoBrush Plus GT to the SurePath
broom does not improve SurePath Pap abnormal cell or
EC recovery.
Diagnostic utility of the SurePath broom with 
supplemental ectocervical and endocervical sampling
As shown above, use of an endocervical sampling device
in addition to the SurePath broom did not enhance the
usefulness of the SurePath Pap. To determine if a spatula
plus an EC brush increased recovery of diagnostic cells
over the SurePath broom, ectocervical spatulas from Rov-
ers and Medscand were examined. Tables 3 and 4 show
results of women who were first sampled with the
Table 1: Broom Followed By Rovers Endocervix Brush
Broom Diagnosis EC Rovers Diagnosis EC Cervical Biopsy 
Diagnosis
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes QNS No Ø
NIL Yes QNS No Ø
LSIL Yes QNS No LSIL
*EC, endocervical cells; NIL, negative for intraepithelial lesion; QNS, quantity not sufficient for diagnosis; Ø, no biopsy performed
P value for diagnosis: paired t test = 0.14, Sign Test = 0.25, Wilcoxon = 0.25
P value for presence of ECs: paired t test = 0.08, Sign Test = 0.25, Wilcoxon = 0.25
Table 2: Broom Followed By Medscand CytoBrush Plus GT
Broom Diagnosis EC Medscand Diagnosis EC Biopsy Diagnosis
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL No Ø
ASC-US Yes ASC-US Yes NIL
HSIL Yes HSIL Yes HSIL
HSIL Yes HSIL Yes HSIL
*EC, endocervical cells; NIL, negative for intraepithelial lesion; QNS, quantity not sufficient for diagnosis; Ø, no biopsy performed
P value for diagnosis: paired t test = 1.0, Sign Test = 1.0, Wilcoxon = 1.0
P value for presence of ECs: paired t test = 0.36, Sign Test = 1.0, Wilcoxon = 1.0BMC Women's Health 2004, 4:6 http://www.biomedcentral.com/1472-6874/4/6
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SurePath broom then immediately re-sampled with either
a Rovers spatula + endocervix brush (Table 3) or a Meds-
cand PAP Perfect Spatula + CytoBrush Plus GT (Table 4).
In group 3 patients (Table 3), 4/11 had abnormal cytology
(1 AGUS, 3 LSIL) identified by use of the SurePath broom.
EC cells were identified in 11/11 cases. Immediate re-sam-
pling of group 3 patients using the Rovers devices resulted
in 4 abnormal Pap diagnosis (2 ASC-US, 1 LSIL, 1 LSIL +
AGUS) in the same four women. Complete diagnosis con-
cordance, however, was seen in only one case. Follow-up
cervical biopsy of these abnormals demonstrated 1
chronic cervicitis, 2 LSIL and 1 HSIL.
When group 4 patients were examined cytologically after
sampling with the SurePath broom (Table 4), 1/11
patients had LSIL and 1/8 patients had HSIL. EC cells were
identified in 10/11 patients. Immediate re-sampling of
group 4 patients with the Medscand spatula + EC brush
yielded 2 diagnoses of ASC-US and 1 QNS. EC cells were,
again, identified in 10/11 patients, however, the patients
lacking EC cells with the SurePath and Medscand devices
were not concordant. Follow-up cervical biopsy con-
firmed the SurePath broom results as LSIL and HSIL.
Taken together these findings indicate that addition of
both a spatula plus a brush device does not alter SurePath
Pap diagnoses but may enhance EC cell detection.
Discussion
We have previously shown that the majority (88%) of
SurePath Pap limited by diagnoses are due to lack of an
EC component [6]. To overcome this problem, some cli-
nicians have turned to using additional devices (usually
Table 3: Broom Followed By Rovers Endocervix Brush + Rovers Spatula
Broom Diagnosis EC Rovers Diagnosis EC Cervical Biopsy 
Diagnosis
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
AGUS Yes ASC-US Yes Chronic Cervicitis
LSIL Yes ASC-US Yes LSIL
LSIL Yes LSIL Yes LSIL
LSIL Yes LSIL, AGUS Yes HSIL
*EC, endocervical cells; NIL, negative for intraepithelial lesion; Ø, no biopsy performed
P value for diagnosis: paired t test = 0.34, Sign Test = 1.0, Wilcoxon = 1.0
P value for presence of ECs: paired t test = 1.0, Sign Test = 1.0, Wilcoxon = 1.0
Table 4: Broom Followed By Medscand CytoBrush Plus GT + Medscand Pap Perfect Spatula
Broom Diagnosis EC Medscand Diagnosis EC Cervical Biopsy 
Diagnosis
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes NIL Yes Ø
NIL Yes QNS No Ø
NIL No NIL Yes Ø
LSIL Yes ASC-US Yes LSIL
HSIL Yes ASC-US Yes HSIL
*EC, endocervical cells; NIL, negative for intraepithelial lesion; QNS, quantity not sufficient for diagnosis; Ø, no biopsy performed
P value for diagnosis: paired t test = 0.1, Sign Test = 0.25, Wilcoxon = 0.25
P value for presence of ECs: paired t test = 0.34, Sign Test = 1.0, Wilcoxon = 1.0BMC Women's Health 2004, 4:6 http://www.biomedcentral.com/1472-6874/4/6
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an EC brush) in combination with the SurePath broom to
attempt to increase the EC yield. The presumed rationale
for use of an EC brush with the SurePath broom is that
broom-type instruments do not reach into the cervical os
as far as stand-alone brushes nor do they have bristles that
are perpendicular to the handle. These concerns appear
anecdotal but have concerned clinicians enough that Tri-
Path Imaging sought and received recent approval for
expanded labeling claims from the FDA to allow use of a
spatula + brush combination with the SurePath Pap [10].
Our study was designed to test whether additional devices
when used in combination with the SurePath broom
enhanced recover of ECs or added diagnostic value to the
SurePath Pap. The reason this study was undertaken was
to demonstrate if the SurePath broom device was suffi-
cient for obtaining an appropriate Pap sample. The strat-
egy involved used a sequential testing method to show
that added sampling of the cervix with spatula and/or
brush devices did not recovery additional abnormal cells
or additional ECs that altered the diagnostic results. These
non-broom devices have different shapes and tinctoral
qualities than the broom device, therefore, it is possible
that they may sample portions of the cervix inaccessible to
the broom, although no published evidence of such qual-
ities exists. Importantly, this study was not designed to
compare the SurePath broom to other devices used in the
collection of SurePath Paps, instead, it was to designed to
probe whether the SurePath broom alone was an appro-
priate device. This is important in light of the aforemen-
tioned SurePath Pap expanded labeling claim where
clinicians might interpret such new FDA labeling as a
repudiation of the broom device in favor of the spatula +
brush combination. Currently, there is no available data
detailing the results of this expanded labeling claim.
In this study, we found that 3% of women sampled with
just the SurePath broom lacked EC cells. These findings
were consistent with but better than our previous report
based on 3,994 women in which we found that 6% of
SurePath Paps were "satisfactory for evaluation but lim-
ited by no EC cells" [6]. Other studies using a broom-type
device have reported a range of EC absence from as low as
4.38% to as high as 29.2% [4,11-16]. This considerable
variability in EC recovery is not easily understood nor is it
clear why in only one [11] of these seven other studies was
the absence of ECs lower than our previously observed
rate of 6%. The next lowest EC absence rate observed in
these seven studies was 10.1% [13]. In our current inves-
tigation, the likely reason why our EC absence rate was
lower than our previous findings [6] was the use of a sin-
gle nurse practitioner to collect all samples. Important to
the SurePath broom is the flat and rounded sides to each
bristle. Counterclockwise rotation brings the rounded
bristle edges in contact with the cervix instead of the flat
side reducing device effectiveness. In addition, a single
experienced collector is more likely to achieve a satisfac-
tory Pap sample than multiple inexperienced Pap collec-
tors [17]. Another important reason why our previous and
current studies show a relative low EC absence rate is that
these studies utilized liquid-based Pap preparation. Most
previous studies focusing on broom-type devices have
compared their effectiveness to other sampling devices
using traditional preparation. As we have shown, the Sure-
Path Pap reduces by 33% limited bys due to lack of ECs
when compared to the traditional Pap [6].
Debate over cervical sampling devices often focuses on EC
sampling. Unfortunately, few studies are available that
report both the EC absence rate and the abnormal cell
detection rate in studies where multiple devices are com-
pared. The retrospective study by Boon et al [11] stands
out in that it suggests that there is a correlation between
lack of endocervical cell recover with the Rovers Cervex-
Brush and reduced detection of CIN III. Most other studies
Sampling Devices Figure 1
Sampling Devices. A, SurePath broom. B, Rover spatula. C, 
Rover endocervix brush. D, Medscand spatula. E, Medscand 
CytoBrush Plus GT.
AB CDEBMC Women's Health 2004, 4:6 http://www.biomedcentral.com/1472-6874/4/6
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have shown equivalence between spatula + EC brush and
broom-type devices. In fact, Buntinx et al in a meta-analy-
sis of 29 trials that included 85,000 patients concluded
that there was no significant difference between spatula +
cotton swab or EC brush, extended tip spatula or broom-
type device in recovery of abnormal cells [18]. This analy-
sis did underscore that use of just an EC brush, cotton
swab or Ayre spatula alone is inappropriate. Interestingly,
they also found that obtaining a second cervical sample
immediately after the first, even with the same device,
increased abnormal cell detection by nearly 33%. We, as
Tables 1,2,3,4 demonstrate, did not see this benefit when
using multiple devices. In the 37 patients we immediately
re-sampled after use of the SurePath broom, no additional
abnormal diagnoses were rendered nor was additional
diagnostic material provided that clarified a SurePath
broom collected indeterminate diagnosis.
As with any study, the strength of statistical analysis
increases as the sample size is increased. However, even
with small sample sizes, compelling results can be
obtained if the statistical significance is large. Here the
data was analyzed using three different nonparametric sta-
tistical tests (for non-continuous or non-numeric data) to
ensure stringency. In addition, we chose to include the p-
values for each of these statistical tests to show that multi-
ple analyses yield the same result and that no single statis-
tical test was chosen to favor a desired outcome. The
hypothesis being tested, in this study, is that the use of
additional collection devices in conjunction with the
SurePath broom device does not enhance diagnostic util-
ity. Normally, p-values <0.05 indicate that one should
reject the hypothesis being tested and conclude enhanced
utility. In this study, the large p-values generated from
analysis of the data indicate a very high probability that
the hypothesis be rejected and that no enhanced
diagnostic utility is realized with the use of additional col-
lection devices.
Since liquid-based Pap testing is relatively new, little work
has been done to examine sampling device effectiveness
utilizing this technology. Selvaggi et al compared the
ThinPrep broom to the ThinPrep spatula + cytobrush and
the ThinPrep broom +cytobrush [4]. These authors found
that the EC component was missing in 24%, 10% and
13% of cases, respectively. However, no examination of
diagnostic utility was included so it is not clear how these
findings relate to device effectiveness in a liquid-based set-
ting. In addition, their findings differed significantly from
our previous examination of broom + brush combination
using liquid-based preparation. When we examined 23
women for EC adequacy using both the SurePath broom
and an EC brush, we found that the EC brush provided no
additional benefit over the broom in the SurePath Pap [6].
Like the Selvaggi et al study we did not comment on diag-
nostic differences when a secondary device was added but
unlike the Selvaggi et al study we found all broom-only
samples to have EC cells present. Importantly, our current
study is the first to examine diagnosis differences that may
result from adding additional devices to a broom device
in the liquid-based setting. Here we found that 10/37
(27%) of cases had abnormal cytology when the SurePath
broom was used. Immediate re-sampling with a second or
third device did not increase the number of abnormal
cytologies found. In addition, cervical biopsy of all abnor-
mal cytologies was performed and as Tables 1,2,3,4 show
use of additional devices did not improve cytology/tissue
correlation.
In conclusion, the SurePath broom appears to be a very
effective cervix sampling device when coupled with the
SurePath Pap. In 60 patients examined prospectively (37
in this study, 23 in our previous study [6]) only one
patient (1.6%) failed to have EC cells recovered with the
broom device alone. This is in contrast to the Selvaggi et
al study that showed in 432 ThinPrep patients a 10% fail-
ure to detect ECs using two devices [4]. We must note,
however, that the EC adequacy standard was different
between their study and our studies because we defined
EC presence as at least one group of 6 or more EC cells and
they defined it as 10 or more EC and/or squamous meta-
plastic cells singly or in groups. Finally, our current work
is the first to show in the liquid-based setting that the
SurePath broom alone is as effective at identifying abnor-
mal cells as the broom + additional devices.
Conclusions
Use of additional collection devices in conjunction with
the SurePath broom did not enhance diagnostic utility of
the SurePath Pap. A potential but not significant improve-
ment in EC recovery might be seen with the use of three
devices.
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